Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

694
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
694
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

3.6K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.6K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

427
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
427
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

867
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
867
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.2K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.2K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Publisher Correction: Rethinking medical education through systems biology to address complexity.

NPJ systems biology and applications·2026
Same author

Rethinking medical education through systems biology to address complexity.

NPJ systems biology and applications·2026
Same author

Effects of Periodontal Therapy on Cardiovascular Risk Biomarkers: A Systematic Review.

Oral health & preventive dentistry·2025
Same author

Analysis of differences in treating peripheral arterial disease in men and women.

Vascular diseases (Paris, France)·2025
Same author

Unveiling platelet aging with progressive β-galactose exposure as a signature of platelet senescence in humans and mice.

Haematologica·2025
Same author

Aortic Valve Calcification Is Induced by the Loss of ALDH1A1 and Can Be Prevented by Agonists of Retinoic Acid Receptor Alpha: Preclinical Evidence for Drug Repositioning.

Circulation·2025

Related Experiment Video

Updated: Jan 5, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.9K

Resistant Hypertension: Novel Insights.

Guillaume Lamirault1,2, Mathieu Artifoni3, Mélanie Daniel4

  • 1l'institut du Thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.

Current Hypertension Reviews
|October 18, 2019
PubMed
Summary

Resistant hypertension affects 10% of hypertensive patients and carries high cardiovascular risk. Recent research refines definitions and explores treatments like anti-aldosterone drugs, showing promise for managing this severe condition.

Keywords:
Hypertensionadherence to therapyantihypertensive drugsblood pressure measurementmedical devicesresistant hypertensionsecondary hypertension.

More Related Videos

Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

23.0K
Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells
09:29

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Published on: March 5, 2019

6.0K

Related Experiment Videos

Last Updated: Jan 5, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.9K
Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

23.0K
Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells
09:29

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Published on: March 5, 2019

6.0K

Area of Science:

  • Cardiology
  • Nephrology
  • Public Health

Background:

  • Hypertension is a leading global cause of premature death and disability.
  • Resistant hypertension, a severe form, affects approximately 10% of hypertensive individuals.
  • This condition is associated with significantly elevated cardiovascular morbidity and mortality risks.

Purpose of the Study:

  • To review and summarize recent advancements in understanding and managing resistant hypertension.
  • To highlight updated definitions incorporating adherence and lifestyle factors.
  • To discuss current therapeutic strategies and ongoing research.

Main Methods:

  • Review of recent epidemiological studies on resistant hypertension prevalence and risk.
  • Analysis of updated clinical guidelines for diagnosis and work-up.
  • Evaluation of evidence from recent randomized clinical trials on fourth-line therapies and device-based interventions.

Main Results:

  • Refined definitions distinguish apparent from true resistant hypertension, emphasizing adherence.
  • Epidemiological data confirm high cardiovascular risk in resistant hypertension patients, identifying high-risk subgroups.
  • Anti-aldosterone drugs show significant benefits as fourth-line treatment; device-based therapies yield mixed results.

Conclusions:

  • Accurate diagnosis of resistant hypertension requires careful assessment of adherence and reversible causes.
  • Anti-aldosterone agents represent a valuable therapeutic option for resistant hypertension.
  • Further research and clinical trials are needed to optimize management strategies and device-based therapies.